Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) ESA in Native Subjects Who Require Red Blood Cell Transfusions

Trial Profile

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) ESA in Native Subjects Who Require Red Blood Cell Transfusions

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2019

At a glance

  • Drugs Luspatercept (Primary) ; Epoetin alfa
  • Indications Myelodysplastic syndromes
  • Focus Biomarker; Therapeutic Use
  • Acronyms COMMANDS
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 09 Jan 2019 Planned number of patients changed from 300 to 350.
    • 09 Jan 2019 Planned End Date changed from 7 May 2026 to 11 Mar 2026.
    • 09 Jan 2019 Planned primary completion date changed from 2 Jun 2021 to 6 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top